Apolipoprotein News and Research

RSS

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today the initiation of a clinical efficacy trial examining the effects of AC-1204 in patients with mild-to-moderate Alzheimer's disease (AD).

26 Nov 2012

Computational apolipoprotein estimates ‘reliable’ for cardiovascular risk

Computational estimates of apolipoprotein B and apolipoprotein A1 can be used as reliable markers for atherosclerosis, report researchers.

22 Nov 2012

Computational apolipoprotein estimates ‘reliable’ for CV risk

Computational estimates of apolipoprotein B and apolipoprotein A1 can be used as reliable markers for atherosclerosis, report researchers.

21 Nov 2012

New genetic insight into Alzheimer’s disease

A rare mutation in the gene encoding the triggering receptor expressed on myeloid cells 2 has a potent effect on the risk for late-onset Alzheimer’s disease, two studies published in The New England Journal of Medicine suggest.

20 Nov 2012

Intravenous infusion of HDL cholesterol could reduce risk of subsequent heart attack

An intravenous infusion of good cholesterol could reduce the risk of a subsequent heart attack, researchers reported at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012

Apolipoprotein E plays a major role in maintaining arterial softness

Arterial stiffening has long been considered a major risk factor for cardiovascular disease. Keeping arteries soft and supple might reduce disease risk, but the mechanisms of how arteries stave off hardening has remained elusive.

2 Nov 2012

Health benefits of fibrate add-on detected postprandially

Adding fenofibrate to statin treatment significantly improves postprandial triglyceride response over statin treatment alone in individuals with diabetes, show findings from a US study.

18 Oct 2012

Health benefits of fibrate add-on detected postprandially

Adding fenofibrate to statin treatment significantly improves postprandial triglyceride response over statin treatment alone in individuals with diabetes, show findings from a US study.

18 Oct 2012

Modifying factors may be responsible for non-diabetic kidney disease in African-Americans

The high rate of non-diabetic kidney disease in African-Americans is strongly associated with variations in a particular gene. Yet, not everyone who inherits these variations develops the disease.

10 Oct 2012

ApoA-V as a contributor to dyslipidemia in obese children

Insulin may be an important regulator of serum apolipoprotein A-V levels in obese people and may contribute to the development of obesity-associated dyslipidemia, say Japanese researchers.

27 Sep 2012

ApoB no better than current lipid markers in CVD risk prediction

Assessment of apolipoprotein B levels does not seem to improve cardiovascular disease risk prediction over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol, report researchers.

11 Sep 2012

Scientists take step toward developing blood test for Alzheimer's

The possibility of an inexpensive, convenient test for Alzheimer's disease has been on the horizon for several years, but previous research leads have been hard to duplicate.

12 Aug 2012

Topline results from Janssen bapineuzumab Phase 3 trial on mild-to-moderate Alzheimer's

Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype (Study 301).

7 Aug 2012

Exercise benefits influenced by sRAGE levels in diabetes

Increased levels of the soluble form of the receptor for advanced glycation end products may underly the beneficial effects of exercise in patients with Type 2 diabetes, research shows.

3 Aug 2012

Topline results from first of four Phase 3 studies of Pfizer's bapineuzumab for Alzheimer's

Pfizer Inc. announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC (Janssen AI)-led Phase 3 trial of intravenous (IV) bapineuzumab in patients with mild-to-moderate Alzheimer's disease who carry the ApoE4 (apolipoprotein E epsilon 4) genotype.

24 Jul 2012

Does alcohol kill brain cells?

Several origins have been suggested for the idea that alcohol kills brain cells. Some link it to the temperance movement, which called for prohibition of alcohol.

9 Jul 2012

Bees help understand connection between taste perception and metabolic syndromes

Scientists at Arizona State University have discovered that honey bees may teach us about basic connections between taste perception and metabolic disorders in humans. By experimenting with honey bee genetics, researchers have identified connections between sugar sensitivity, diabetic physiology and carbohydrate metabolism. Bees and humans may partially share these connections.

30 Jun 2012

Research examines link between metabolic syndrome and cognitive disorders

No effective treatments are currently available for the prevention or cure of Alzheimer's disease (AD), the most frequent form of dementia in the elderly. The most recognized risk factors, advancing age and having the apolipoprotein E Ɛ4 gene, cannot be modified or treated. Increasingly, scientists are looking toward other risk factors to identify preventive and therapeutic strategies.

15 Jun 2012

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.

2 Jun 2012

People with fatty livers need to lose weight

Exercising moderately for 150 to 300 minutes a week does not improve lipoprotein metabolism in obese people with nonalcoholic fatty lipid disease, show findings from a US study.

31 May 2012